Medication info
Gabapentin Capsule 150 milligrams (Pregabalin)

Gabapentin Capsule 150 milligrams (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Hankook Pharm Co., Ltd.
Appearance
A hard capsule containing white or light yellow powder with a white opaque top and bottom.
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201109275 · Notified 2011.10.31 · Insurance code 645304370

Summary

Main use
Neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy
Who takes it
Adults · Children
Adult dose
This drug is administered orally, with or without food, as pregabalin in 2 divided doses per day. Since this drug is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment.”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment.”) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys unchanged. Since clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula: Creatinine clearance (mL/min)* = [140-age(years)] × body weight (kg)/72 × serum creatinine concentration (serum creatinine, mg/dL) *: For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Initial dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to an additional dose administered once. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Hankook Pharm Co., Ltd.

Efficacy & effects

Neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medicine is used to relieve peripheral and central neuropathic pain in adults, and as an adjunctive treatment for partial seizures in epilepsy patients. It also helps reduce pain due to fibromyalgia. This drug is used effectively to improve symptoms of various neurological disorders and enhance the quality of life for patients.

How to take

Adult dose

This drug is administered orally, with or without food, as pregabalin in 2 divided doses per day. Since this drug is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment.”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment.”) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys unchanged. Since clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula: Creatinine clearance (mL/min)* = [140-age(years)] × body weight (kg)/72 × serum creatinine concentration (serum creatinine, mg/dL) *: For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Initial dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to an additional dose administered once. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medicine may increase the risk of suicidal thoughts or behaviors, so if mood changes or abnormal behaviors occur during treatment, it is essential to inform a healthcare professional. Individuals allergic to any ingredients in this medicine or those with certain genetic disorders should not take it. Diabetic patients should be cautious as they may need to adjust the dosage of blood sugar control medications due to weight gain. If severe allergic reactions such as angioedema occur, the medication should be discontinued immediately. Elderly individuals may be at increased risk of falls due to dizziness or drowsiness, so they should be especially careful in the early stages of treatment. If vision changes such as blurriness occur, patients should consult a doctor. Sudden discontinuation of this drug may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so it should be tapered off gradually under medical supervision. Patients with a history of substance abuse need to be particularly cautious as they have a higher possibility of misuse with this medication. Patients with impaired kidney function may require dose adjustments. Patients with severe heart disease should consult a doctor before taking this drug. Caution is needed when this drug is combined with opioid analgesics as it may intensify central nervous system depression symptoms. Patients with respiratory disease, kidney disease, and the elderly may be at higher risk for severe respiratory depression, and dosage adjustments may be necessary. There is a risk of fetal abnormalities in early pregnancy, so this medication should not be taken during pregnancy, and women of childbearing age should use effective contraception. While breastfeeding, consider discontinuing either the drug or breastfeeding as this drug may pass into breast milk. Before engaging in hazardous activities such as driving or operating machinery, verify whether dizziness or drowsiness occurs due to this medication. In cases of overdose, symptoms such as confusion, drowsiness, depression, and seizures may occur, so immediate medical attention is required. This medicine should be kept out of reach of children and should not be transferred to other containers.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral swelling
  • upper airway swelling
  • dizziness
  • drowsiness
Show 201 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • depression
  • suicidal thoughts
  • pain
  • seizures
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • insomnia
  • depersonalization
  • sexual sensation disorder
  • restlessness
  • anxiety
  • mood disturbance
  • emotional low
  • emotional high
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • dizziness
  • drowsiness
  • ataxia
  • motor coordination abnormality
  • balance disorder
  • memory loss
  • attention disorder
  • memory disorder
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory reduction
  • sedation
  • excessive drowsiness
  • cognitive impairment
  • nystagmus
  • speech disorder
  • kinesogenic tremor
  • reflex reduction
  • motor abnormalities
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • heat sensations
  • activity tremors
  • syncope
  • confusion
  • reduced motor activity
  • olfactory abnormalities
  • taste loss
  • writing difficulties
  • blurred vision
  • diplopia
  • indirect vision loss
  • visual disturbances
  • visual field loss
  • photophobia
  • dry eyes
  • conjunctival swelling
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear production
  • eye irritation
  • mydriasis
  • during vibration
  • changes in visual depth perception
  • strabismus
  • bright vision
  • vertigo
  • auditory hypersensitivity
  • first-degree atrioventricular block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • shortness of breath
  • nasal bleeding
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory reduction
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical muscle spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • intoxicated feeling
  • altered sensations
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorders
  • drowsiness
  • confusional state
  • agitation
  • restlessness
  • worsening of convulsions

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly sealed container to prevent exposure to air or moisture. It is best to maintain a storage temperature between 15 and 30 degrees Celsius. This will help maintain the drug's effectiveness for a longer period.

Appearance and packaging

Appearance

A hard capsule containing white or light yellow powder with a white opaque top and bottom.

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.